Crescent Biopharma (NASDAQ: CBIO) reports $171.6M preliminary cash as of June 30, 2026
Rhea-AI Filing Summary
Crescent Biopharma, Inc. provides a preliminary estimate that cash and cash equivalents were approximately $171.6 million as of June 30, 2026. The figure is unaudited, based on management estimates for the quarter, and may change after completion of financial closing procedures.
The company states that its independent auditor, PricewaterhouseCoopers LLP, has not audited, reviewed, examined, compiled or applied procedures to this data. The information is treated as filed under Section 18 of the Exchange Act and incorporated by reference into certain securities law filings, and is accompanied by forward-looking statement cautions.
Positive
- None.
Negative
- None.
Filing Explained
The July 14 Form 8-K places the preliminary June 30 cash estimate of
8-K Event Classification
Item 2.02 — Results of Operations and Financial Condition
1 item
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Key Figures
Cash and cash equivalents: $171.6 million
Par value per ordinary share: $0.001
2 metrics
Cash and cash equivalents
$171.6 million
Preliminary management estimate as of June 30, 2026
Par value per ordinary share
$0.001
Ordinary Shares, $0.001 par value per share listed on The Nasdaq Capital Market
Key Terms
cash and cash equivalents, forward-looking statements, internal controls over financial reporting, Private Securities Litigation Reform Act of 1995, +1 more
5 terms
cash and cash equivalents financial
"the Company estimates that its cash and cash equivalents were approximately $171.6 million"
Cash and cash equivalents are the money a company has on hand plus very short-term, low-risk investments that can be quickly turned into cash, like bank deposits or government bills. Investors watch this figure because it shows a company’s immediate ability to pay bills, cover unexpected costs, and fund operations or growth — like a household’s checking account and emergency fund that keeps daily life running smoothly.
forward-looking statements regulatory
"statements contained in this report regarding matters that are not historical facts are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
internal controls over financial reporting financial
"completion of review of internal controls over financial reporting or other quarter-end and year-end procedures"
Internal controls over financial reporting are the policies, procedures and checks a company uses to make sure its accounting and financial statements are accurate, complete and free from significant error or fraud. They matter to investors because strong controls lower the risk of misleading results or surprise restatements—think of them as a quality checkpoint on a factory line that helps prevent costly defects that could damage a company’s value and reputation.
Private Securities Litigation Reform Act of 1995 regulatory
"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Section 18 of the Securities Exchange Act of 1934 regulatory
"shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"
Earnings Snapshot
Cash and cash equivalents: $171.6 million
As of June 30, 2026
Cash and cash equivalents
$171.6 million
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What cash balance did Crescent Biopharma (CBIO) estimate as of June 30, 2026?
Crescent Biopharma estimated cash and cash equivalents of approximately $171.6 million as of June 30, 2026. This amount is based on preliminary, unaudited management information for the quarter and may change once financial closing and review procedures are completed.
Is Crescent Biopharma’s (CBIO) $171.6 million cash estimate audited?
No, the $171.6 million cash and cash equivalents estimate is unaudited and based on management’s preliminary data. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, or performed agreed-upon procedures on this information and provides no assurance on it.
Which period does Crescent Biopharma’s (CBIO) preliminary cash figure relate to?
The estimated $171.6 million in cash and cash equivalents relates to Crescent Biopharma’s position as of June 30, 2026. It reflects management’s preliminary view for the quarter ended that date and is subject to change after full quarter-end procedures.
Did PricewaterhouseCoopers review Crescent Biopharma’s (CBIO) preliminary Q2 2026 cash data?
PricewaterhouseCoopers LLP did not audit, review, examine, compile, or apply agreed-upon procedures to Crescent Biopharma’s preliminary cash data. As a result, the audit firm expresses no opinion or other form of assurance on the $171.6 million estimate.
How is Crescent Biopharma’s (CBIO) preliminary cash disclosure treated under U.S. securities laws?
The company states this cash disclosure is deemed “filed” under Section 18 of the Exchange Act and is deemed incorporated by reference into Securities Act and Exchange Act filings, unless a particular filing expressly provides otherwise.
What forward-looking risks does Crescent Biopharma (CBIO) highlight around its preliminary cash estimate?
Crescent Biopharma notes that actual results for Q2 or full-year 2026 may differ materially from the preliminary estimate. Changes in assumptions, completion of internal controls review, and other quarter-end or year-end procedures could alter the reported cash position.